Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
VYGR
Voyager Therapeutics, Inc.
Voyager’s core offerings are gene therapies and gene-delivery platforms, including APOE and tau-targeted approaches.
|
$253.99M |
$4.20
-8.50%
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
Direct product: vaccines pipeline and KOSTAIVE vaccine production and commercialization.
|
$252.22M |
$8.96
-3.66%
|
|
PBYI
Puma Biotechnology, Inc.
Direct oncology biotech core product portfolio with Nerlynx and alisertib being cancer therapies.
|
$250.18M |
$4.92
-2.38%
|
|
LRMR
Larimar Therapeutics, Inc.
Nomlabofusp is a recombinant fusion protein, i.e., a recombinant protein/enzyme therapeutic.
|
$248.43M |
$3.85
-0.90%
|
|
ALMS
Alumis Inc. Common Stock
Alumis is developing oral TYK2 inhibitors (ESK-001 and A-005), a major product category of oral small molecule therapeutics.
|
$248.09M |
$4.53
-0.77%
|
|
HUMA
Humacyte, Inc.
Humacyte's Symvess is a vascular conduit/endovascular device used for extremity vascular trauma—fits Vascular Intervention Devices.
|
$246.64M |
$1.50
-5.35%
|
|
ABEO
Abeona Therapeutics Inc.
ZEVASKYN is an autologous cell-based therapy (cell therapy) targeting RDEB wounds.
|
$244.53M |
$4.52
-5.44%
|
|
LYEL
Lyell Immunopharma, Inc.
Lyell’s lead program LYL314 is a CAR-T cell therapy product targeting cancer (CD19/CD20 dual-target), the core business.
|
$244.39M |
$16.32
-1.36%
|
|
MGRM
Monogram Orthopaedics, Inc.
Direct product category: Monogram's system is a surgical device used in operating rooms for orthopedic procedures.
|
$243.79M |
$6.00
|
|
STXS
Stereotaxis, Inc.
Catheter-based cardiology devices (ablation/catheters) are a core direct product, fitting Cardiology Devices.
|
$239.08M |
$2.73
-1.98%
|
|
ASMB
Assembly Biosciences, Inc.
Assembly Biosciences develops small-molecule antiviral therapeutics, including HSV helicase-primase inhibitors, HDV entry inhibitors, HBV capsid assembly modulators, and NNPI programs.
|
$238.06M |
$31.60
+1.38%
|
|
IMRX
Immuneering Corporation
Atebimetinib (IMM-1-104) is an oral small-molecule therapeutic in clinical trials.
|
$236.07M |
$6.32
-3.73%
|
|
PYXS
Pyxis Oncology, Inc.
Pyxis Oncology is a biotechnology company focused on oncology therapeutics, with MICVO as its lead asset in cancer.
|
$236.02M |
$3.92
+2.76%
|
|
CLLS
Cellectis S.A.
Lead assets UCART22 and UCART20x22 are allogeneic cell therapies (CAR-T) directly developed and manufactured by the company.
|
$235.75M |
$3.29
+0.46%
|
|
FHTX
Foghorn Therapeutics Inc.
Clinical-stage biotech focused on oncology therapies targeting chromatin regulatory system (SMARCA2/BRG1, CBP/EP300, ARID1B degraders), a cancer-focused platform.
|
$234.67M |
$3.47
-17.58%
|
|
SNWV
SANUWAVE Health, Inc.
SANUWAVE directly manufactures and markets medical devices (UltraMIST and related wound-care technology) and biometrics for patient care.
|
$234.59M |
$27.50
+0.31%
|
|
NAUT
Nautilus Biotechnology, Inc.
The hardware/assay suite functions as diagnostic-type equipment for proteomics analyses.
|
$233.66M |
$1.53
-17.03%
|
|
TNYA
Tenaya Therapeutics, Inc.
Tenaya's lead programs TN-201 and TN-401 are gene therapies (AAV-based) targeting genetic heart diseases.
|
$232.61M |
$1.40
-2.45%
|
|
ENTA
Enanta Pharmaceuticals, Inc.
Enanta is actively developing antiviral small-molecule therapeutics targeting RSV, fitting the Antiviral Small-Molecule Therapeutics theme.
|
$231.29M |
$11.12
+2.77%
|
|
OM
Outset Medical, Inc.
Outset's Tablo Hemodialysis System is a medical device; tag as Medical Devices & Biometrics.
|
$230.57M |
$12.63
-2.88%
|
|
DRUG
Bright Minds Biosciences Inc.
Directly relates to development of neuropsychiatric/CNS therapeutics targeting serotonin receptors.
|
$229.71M |
$52.00
+1.05%
|
|
SLRN
Acelyrin, Inc.
Lonigutamab is a monoclonal antibody therapeutic (IGF-1R) being developed as a treatment for TED, aligning with Monoclonal Antibody Therapeutics.
|
$228.61M |
$2.27
|
|
ZURA
Zura Bio Limited
Zura Bio develops immunology therapeutics for autoimmune and inflammatory diseases (Immunology Therapeutics).
|
$227.70M |
$3.54
-3.67%
|
|
SLSN
Solesence, Inc. Common Stock
Solésence operates as a contract development and manufacturing organization (CDMO) for beauty products, matching Contract Manufacturing Organizations.
|
$226.43M |
$3.13
-3.10%
|
|
CRBU
Caribou Biosciences, Inc.
Company is developing gene-editing gene therapy platforms (CRISPR-based chRDNA) for therapeutic applications.
|
$226.00M |
$2.25
-7.61%
|
|
AARD
Aardvark Therapeutics, Inc. Common Stock
ARD-101 and ARD-201 are oral small-molecule therapeutics targeting satiety pathways for metabolic and rare-disease indications.
|
$225.42M |
$10.13
-2.45%
|
|
PRLD
Prelude Therapeutics Incorporated
Prelude is a clinical-stage biotech focused on oncology, with an advanced pipeline targeting SMARCA2/SMARCA4 and related cancer pathways.
|
$224.71M |
$1.64
-58.79%
|
|
BDTX
Black Diamond Therapeutics, Inc.
BDTX operates as a biotechnology company focused on oncology therapeutics, i.e., Biotech - Oncology.
|
$224.61M |
$3.71
-5.95%
|
|
FENC
Fennec Pharmaceuticals Inc.
Direct product in oncology/supportive care with FDA-approved PEDMARK therapy for cisplatin-induced ototoxicity.
|
$224.54M |
$8.15
+0.25%
|
|
INGN
Inogen, Inc.
Company manufactures medical devices and respiratory care equipment (POCs, SOCs, Simeox), a core medical devices business.
|
$220.74M |
$8.08
-1.58%
|
|
PRQR
ProQR Therapeutics N.V.
ProQR's Axiomer platform uses oligonucleotide-based RNA editing (EONs) to direct ADAR-mediated editing.
|
$218.20M |
$2.42
-6.56%
|
|
INFU
InfuSystem Holdings, Inc.
InfuSystem directly provides infusion pumps and related medical device equipment, plus lifecycle management services.
|
$218.14M |
$9.40
-9.57%
|
Showing page 21 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
